CytRx released some unimpressive overall survival rates from its Phase IIb study of its aldoxorubicin compared with doxorubicin for soft tissue sarcoma. Overall median OS in the drug arm was 16 months, compared with an uncomfortably close 14 months in the comparison arm of the study. The biotech, though, noted that the study had not been powered to produce statistically significant results. CytRx ($CYTR) shares slipped slightly on the news this morning. Just yesterday the FDA lifted a partial hold on the late-stage program. Release